Answers are grounded in this paper and cite their sources.
José M. Carballido, Executive Director at Novartis Institutes for BioMedical Research, and Pere Santamaria, Professor of Immunology at the University of Calgary and Founder of Parvus Therapeutics Inc., discuss the opportunities and challenges of translating antigen-specific approaches for autoimmunity with an emphasis on the need for scientific rigor in the preclinical stage.
No takes yet. Share an insight, caveat, or question.
Carballido et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: